Provectus: PV-10 Abstract Published; New Presentation Planned

September 24, 2014

The ESMO abstract entitled, "Subgroup efficacy in patients receiving intralesional rose bengal to all existing melanoma in phase II study PV-10-MM-02," to be presented at the European Society for Medical Oncology 2014 Congress, is now available, reports Provectus Biopharmaceuticals, Inc.
The ESMO 2014 Congress in Madrid, Spain, runs from September 26-30, 2014. This poster presentation will be held on Sunday, September 28, 2014, beginning at 12:45 pm local time, presented by Sanjiv S. Agarwala, MD, of St. Luke's Hospital and Health Network, Bethlehem, PA.
Dr. Craig Dees, PhD, CEO of Provectus, said, "We are very pleased that these subgroup data will be presented at ESMO this year, and we are glad that our principal investigator Dr. Agarwala will be available to discuss this work with attendees.” Provectus also announced that a team of researchers led by Shari Pilon-Thomas, PhD from the Moffitt Cancer Center will present data at the Society for Immunotherapy of Cancer [SITC] 29th Annual Meeting with an abstract titled “Efficacy of Intralesional Injection with PV-10 in Combination with Co-Inhibitory Blockade in a Murine Model of Melanoma.”
PV-10, a 10% solution of Rose Bengal that is currently being investigated as a potential cancer therapeutic, is designed for injection into solid tumors (intralesional administration).

Facebook Comments


We’re glad to see you’re enjoying PracticalDermatology…
but how about a more personalized experience?

Register for free